Concurrent candidemia and candiduria in intensive care unit patients: A retrospective evaluation: Concurrent Candidemia and Candiduria

Rabiye Altınbaş; Selda Aslan

doi:10.5281/zenodo.19208823

Authors

Rabiye Altınbaş İzmir City Hospital, Department of Medical Microbiology, İzmir, Turkey https://orcid.org/0000-0003-2535-0480
Selda Aslan Gaziantep City Hospital, Department of Infectious Diseases and Clinical Microbiology, Gaziantep, Turkey https://orcid.org/0000-0001-8695-7118

DOI:

https://doi.org/10.5281/zenodo.19208823

Keywords:

Antifungal treatment, invasive candidiasis, urinary tract infections, yeast

Abstract

Objective: This study aimed to improve understanding of the management of such cases by evaluating risk factors in patients with concomitant candidemia and candiduria.

Methods: Microbial identification of clinical isolates at the species level was performed using the VITEK^®2 automated system, and antifungal susceptibility was evaluated using the colorimetric microdilution method.

Results: The majority of patients with concurrent candiduria and candidemia were hospitalized in medical intensive care units. Prior antibiotic use was the most frequently observed predisposing factor. A total of 57 episodes of simultaneous candidemia and candiduria were identified. Candida albicans was the most frequently isolated species, whereas non-albicans Candida (NAC) accounted for 68.4% of cases. The majority of Candida isolates were pan-susceptible. Most isolates were susceptible to amphotericin B (7/11, 63.6%), except for Candida auris. Fluconazole resistance was the most frequently identified resistance pattern, detected in all C. auris isolates (11/11, 100%) and in 3 isolates of the C. parapsilosis complex (3/10, 30%). Moreover, 2 isolates of the C. parapsilosis complex (2/10, 20%) exhibited resistance to voriconazole, whereas isolates of C. albicans and C. tropicalis remained susceptible. Additionally, 2 isolates of C. albicans (2/18, 11%) showed resistance to both anidulafungin and micafungin, and 1 isolate of Candida glabrata (1/5, 20%) showed resistance to micafungin. Fluconazole was the most commonly used first-line antifungal agent. Mortality was higher among patients with C. albicans candidemia.

Conclusion: This study provides further insight into the association between candiduria and candidemia, offering valuable information to guide clinical practice.

References

1. Ngai PV, Dat TH, Nhi LY, Linh TTK, Thu NT, Anh VL, et al. Distribution and antifungal susceptibility of Candida species causing vulvovaginal candidiasis and urinary tract infection in Medlatec healthcare system, Ha Noi city, Vietnam in 2023. Ther Adv Infect Dis. 2025;12:1–10.

2. Pemán J, Ruiz-Gaitán A. Candidemia from urinary tract source: the challenge of candiduria. Hosp Pract (1995). 2018;46:243–5.

3. Horasan EŞ, Kandemir Ö, Göksu M, Sevim Karaçorlu S, Kaya A. Candiduria in Urine Samples from Critically Ill Patients and Candidemia. Flora. 2011;16:77–81.

4. He Z, Su C, Bi Y, Cheng Y, Lei D, Wang F. Evaluation of a novel laboratory candiduria screening protocol in the intensive care unit. Infect Drug Resist. 2021;14:489–96.

5. Zhao L, Xu LF, Xiang GD, Zhou QC, Wang Y, Li GY. Multi-locus sequence typing of Candida tropicalis among Candiduria shows an outbreak in azole-susceptible isolates and clonal cluster enriched in azole-resistant isolates. J Hosp Infect. 2025;156:96–105.

6. Mazzitelli M, Nalesso F, Maraolo AE, Scaglione V, Furian L, Cattelan A. Fungal infections in kidney transplant recipients: a comprehensive narrative review. Microorganisms. 2025;13:1–14.

7. Ceylan İ, Korkmaz HA, Karakoç E. Evaluation of patients with candida infections in a tertiary care hospital’s general intensive care unit in Turkey. Crit Care Innov. 2022;5:1–10.

8. Korulmaz A, Alakaya M, Arslankoylu AE, Kaya S, Erdoğan S, Ozgur D, et al. Distribution of candida species and risk factors for invasive candidiasis. Ege Tıp Derg. 2022;61:616–25.

9. Nascimento T, Inácio J, Guerreiro D, Diaz P, Patrício P, Proença L, et al. Susceptibility patterns of Candida species collected from intensive care units in Portugal: a prospective study in 2020–2022. Infect Prev Pract. 2024;6:100403.

10. Sachu A, Sunny S, Mathew P, Kumar A, David A. Time to positivity of blood cultures causing candidemia and its relation to mortality. Iran J Microbiol. 2024;16:263–72.

11. Nagata J, Kawasaki T, Iesato K, Sugiura T, Yamauchi K, Tsuyusaki J, et al. A case of candidemia after long-term presence of urethral foreign bodies. IDCases. 2021;25:e01176.

12. Hwang SY, Lim YK, Choe KW, Choi Y, Lee M. Seasonality and epidemiological trends in species distribution and antifungal susceptibility of Candida species isolated from various clinical specimens conducted during 2011 – 2022 , Korea : a retrospective surveillance study. Ann Clin Microbiol. 2024;27:185–96.

13. Benders PMB, Schouten J, Vena A, Buil JB, Bronkhorst E, Bassetti M. Creating a prediction model for invasive candidiasis in the intensive care unit using a case control design : a European multicentre approach. BMC Infect Dis. 2025;25:655.

14. Elbaz M, Chikly A, Meilik R, Ben-Ami R. Frequency and clinical features of Candida bloodstream infection originating in the urinary tract. J Fungi. 2022;8:4–13.

15. Yapar N, Kose H, Ergon MC, Savran Y, Doluca M, Oguz VA. Candiduria among intensive care unit patients undergoing urinary catheterization: risk factors, effect on candidemia and mortality. Flora. 2015;20:195–202.

16. Wang K, Hsueh K, Kronen R, Lin C, Salazar AS, Powderly WG, et al. Creation and assessment of a clinical predictive model for candidaemia in patients with candiduria. Mycoses. 2019;62:554–61.

17. Drogari-Apiranthitou M, Anyfantis I, Galani I, Kanioura L, Daikos GL, Petrikkos G. Association between candiduria and candidemia: a clinical and molecular analysis of cases. Mycopathologia. 2017;182:1045–52.

18. Ahmed ME, Aldeen SMS, Amr GE, Salem AMAA. Incidence and risk factors of funguria in nosocomial septic patients in surgical intensive care unit. Egypt J Hosp Med. 2022;87:1608–12.

19. Ashraf AA, Karnaker VK, Ramanath G, Roy A, Raveendran ASN. Frequency and antifungal susceptibility patterns of Candida species isolated from clinical samples of patients attending to a tertiary healthcare setting in Karnataka, India. J Nat Sci Med. 2020;3:299.

20. Dolatabadi S, Najafzadeh MJ, Raeisabadi A, Zarrinfar H, Jalali M, Spruijtenburg B, et al. Epidemiology of Candidemia in Mashhad, Northeast Iran: A Prospective Multicenter Study (2019–2021). J Fungi. 2024;10:481.

21. Suárez-Urquiza P, Pemán J, Gordon M, Favier P, Muñoz-Brell P, López-Hontangas JL, et al. Predicting fungemia in the ICU: unveiling the value of weekly fungal surveillance and yeast colonisation monitoring. J Fungi. 2024;10:674.

22. Bilgin MK, Talan L, Evren E, Altıntas ND. Retrospective evaluation of risk factors for invasive Candida infections in a medical intensive care unit. Infect Dis Clin Microbiol. 2022;4:62–71.

23. Sanlı K, Arslantaş E, Ceylan AN, Öncel B, Özkorucu D, Karagenç AO. Candidemia in pediatric-clinic: frequency of occurrence, Candida species, antifungal susceptibilities, and effects on mortality (2020–2024). Diagnostics. 2024;14:2343.

24. Biagi MJ, Wiederhold NP, Gibas C, Wickes BL, Lozano V, Bleasdale SC, et al. Development of high-level echinocandin resistance in a patient with recurrent Candida auris candidemia secondary to chronic candiduria. Open Forum Infect Dis. 2019;6:1–5.

25. Meneghello S, Bernabè G, Di Pietra G, Di Sopra S, Del Vecchio C, Cattelan AM, et al. Prevalence, species distribution and resistance of candidemia in pediatric and adult patients in a northeast Italy university hospital. J Fungi. 2024;10:707.

26. Odoj K, Garlasco J, Pezzani MD, Magnabosco C, Ortiz D, Manco F, et al. Tracking candidemia trends and antifungal resistance patterns across Europe: an in-Depth analysis of surveillance systems and surveillance studies. J Fungi. 2024;10:685.

27. Arendrup MC, Arikan-Akdagli S, Jørgensen KM, Barac A, Steinmann J, Toscano C, et al. European candidaemia is characterised by notable differential epidemiology and susceptibility pattern: Results from the ECMM Candida III study. J Infect. 2023;87:428–37.

28. Arikan-Akdagli S, Gülmez D, Doğan Ö, Çerikçioğlu N, Doluca Dereli M, Birinci A, et al. First multicentre report of in vitro resistance rates in candidaemia isolates in Turkey. J Glob Antimicrob Resist. 2019;18:230–4.

Concurrent candidemia and candiduria in intensive care unit patients: A retrospective evaluation